Biopharma & Life Sciences
Caribou Biosciences Executive Compensation (FY25)
CRBU · Executive and director compensation, fiscal 2022 to 2025
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Caribou Biosciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of October 11, 2026Latest filing (DEF 14A): May 1, 2026
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
The Pay Desk is the free weekly executive pay briefing — one company at a time, every number traceable to a public filing.You’ll confirm on The Pay Desk’s sign-up page.
$1,500Get the executive brief
176 figures on this page, cited to the filing that reported them. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Rachel Haurwitz: $4,213,245 → $1,840,965 (56.3% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Caribou Biosciences' chief executive and what were they paid?
Rachel Haurwitz was paid $1,840,965 in total compensation as President and chief executive officer for fiscal 2025. Compared with the $4,213,245 reported for fiscal 2024, Haurwitz's total was 56.3% lower.
What was Caribou Biosciences' say-on-pay result?
The company is an emerging growth company and is exempt from the advisory say-on-pay vote.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Syed Rizvi Chief medical officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Ruhi Khan Chief business officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Rachel Haurwitz President and chief executive officer | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Rachel Haurwitz President and chief executive officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Syed Rizvi Former chief medical officer Departed during or after this year | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Steven Kanner Chief scientific officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Barbara McClung Chief legal officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Rachel Haurwitz President and chief executive officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Tim Kelly Chief technology officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Steven Kanner Chief scientific officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Barbara McClung Chief legal officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Rachel Haurwitz President and chief executive officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Sriram Ryali Chief financial officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Barbara McClung Chief legal officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Barbara McClung | PSU | ◇ | — | ◇ | — | — | — | — |
| Barbara McClung | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Barbara McClung | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Rachel Haurwitz | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Rachel Haurwitz | PSU | ◇ | — | ◇ | — | — | — | — |
| Rachel Haurwitz | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Sriram Ryali | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Sriram Ryali | PSU | ◇ | — | ◇ | — | — | — | — |
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Rachel Haurwitz | Option | ◇ | — | ◇ | 02/19/2034 |
| Option | ◇ | — | ◇ | 02/20/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 02/19/2035 | |
| Option | ◇ | — | ◇ | 07/20/2035 | |
| Barbara McClung | Option | ◇ | — | ◇ | 02/19/2034 |
| Option | ◇ | — | ◇ | 07/20/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 02/19/2035 | |
| Option | ◇ | — | ◇ | 02/20/2033 | |
| Sriram Ryali | Option | ◇ | — | ◇ | 01/09/2035 |
| Option | ◇ | — | ◇ | 07/20/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Barbara McClung
Chief legal officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Excise tax treatment | ◇ |
Rachel Haurwitz
President and chief executive officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Excise tax treatment | ◇ |
Sriram Ryali
Chief financial officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Excise tax treatment | ◇ |
| Clawback | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Andrew Guggenhime | ◇ | — | ◇ | — | — | — | ◇ |
Ran Zheng | ◇ | — | ◇ | — | — | — | ◇ |
Nancy Whiting | ◇ | — | ◇ | — | — | — | ◇ |
Natalie Sacks | ◇ | — | ◇ | — | — | — | ◇ |
Dara Richardson-Heron | ◇ | — | ◇ | — | — | — | ◇ |
Scott Braunstein | ◇ | — | ◇ | — | — | — | ◇ |
David Johnson | ◇ | — | ◇ | — | — | — | ◇ |
Rachel Haurwitz served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
This company is an emerging growth company and is exempt from the advisory vote on executive compensation. There is no vote to report.
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Rachel Haurwitz (President and chief executive officer), FY2025 total compensation $1,840,965 (base salary $667,534) [exec_comp, SEC accession 0001619856-26-000028, filed 2026-05-01]What this page does not include
Everything above is a fact Caribou Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
176 figures on this page, cited to the filing that reported them.
176 cited to the filing
Documents cited
- 0001619856-26-000028EXECUTIVE AND DIRECTOR COMPENSATION
- 0001619856-26-000022Compensation Discussion and Analysis · EXECUTIVE AND DIRECTOR COMPENSATION · Summary Compensation Table
- 0001619856-25-000031Summary Compensation Table (2024 and 2023)
- 0001619856-24-000026
- 0001619856-23-000063
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Caribou Biosciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CRBU (accessed 2026).
Short form: data: Velarion
The Caribou Biosciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Caribou Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}